Serum microRNA‐501‐3p is a potential diagnostic tool for detecting mild cognitive impairment: Ehime genome study

Abstract Tight junction disruption and dysfunction are involved in the progression of blood–brain barrier (BBB) breakdown. Recent investigations have revealed BBB disruption in patients with vascular cognitive decline. Our previous studies showed that miR‐501‐3p negatively regulates cerebral endothelial tight junction protein‐1, resulting in the disruption of the BBB, and playing an important role in the development of vascular cognitive impairment. BBB breakdown in white matter lesions is often seen in the patients with vascular mild cognitive impairment (MCI). We therefore hypothesize that most early‐phase MCI patients may demonstrate elevated expression of miR‐501‐3p and sought to investigate whether serum exosome miR‐501‐3p levels could be a clinical indicator for detecting mild cognitive impairment. One hundred and seventy‐eight subjects (aged 73 [68–75] years, 53% male) were recruited for this study. The Japanese version of the Montreal Cognitive Assessment (MoCA‐J) was used for detecting MCI. Serum exosome miR‐501‐3p expression levels were measured by qPCR methods. Patients were divided into two groups depending on whether their miR‐501‐3p ∆Ct values were above (“High”; n = 74) or below (“Low”; n = 104) cutoff levels determined by ROC curve. MCI was detected significantly more often in the miR‐501‐3p‐High group (vs. ‐Low group, 63.5% vs. 47.1%, respectively; p < 0.05). Multivariate logistic regression analysis showed a significant association between MCI status and High miR‐501‐3p (odds ratio 2.662; p < 0.01), improved vs. known risk factors. In non‐diabetic patients, High miR‐501‐3p was positively associated with MCI status (odds ratio 3.633; p < 0.01) and also positively associated with MCI status in those with atherosclerosis (odds ratio 3.219; p < 0.01). The present study demonstrates that elevated expression of blood exosomal miR‐501‐3p can indicate the presence of MCI in human patients. Early detection of vascular injuries may allow a reduction in progressive dementia through the management of vascular risk factors. image